普拉克索添加治疗帕金森病的临床研究  

作　　者：葛许华[1] 于春雨[1] 孔德莲[1] 秦敬翠[1] 周联生[1] 

机构地区：[1]江苏省徐州市第一人民医院神经内科,221002

出　　处：《浙江临床医学》2011年第10期1094-1096,共3页Zhejiang Clinical Medical Journal

摘　　要：目的观察添加普拉克索治疗帕金森病（PD）的疗效和安全性。方法84例PD患者在原左旋多巴治疗的基础上随机分成三组，普拉克索组加用普拉克索0．125mg，2次／d，6周滴定至1．5mg／d，并维持此剂量，共12周，多巴丝肼用量根据患者病情减少0．075～3．375g；溴隐亭组加用溴隐亭，起始剂量1．25mg／d，至第2周末渐加至5．0m。g／d，分2～3次口服，12周为1个疗程，多巴丝肼用量根据患者病情减少0．075—3．375g；对照组除继续服用左旋多巴（多巴丝肼）且不减量外，不加其他药。治疗前后用统一PD评定量表（UPDRS）评分评估疗效，并观察不良反应。结果普拉克索组总有效率86．67％，明显优于溴隐亭组的75．00％和对照组的3．85％；不良反应发生率普拉克索组与溴隐亭组两组之间差异无统计学意义。结论对于正在服用左旋多巴治疗的患者加服普拉克索，可以缓解其运动症状，降低左旋多巴用量及减少、改善左旋多巴的不良反廊。Objective To observe the efficacy and safety of pramipexole＇s add - on therapy in Parkinson＇s disease （ PD ）. Methods 84 patients with Parkinson＇s disease in the original basis of levodopa therapy were randomly divided into 3 groups： Pramipexole group were treated with Pramipexole 0. 125mg, 2 times a day, 6 weeks titration to 1.5mg / d, and maintain this dose for 12 weeks; Bromocriptine group were treated with bromocriptine starting dose of 1.25mg/d, gradually increase to 2 week to 5.0mg / d, 2 - 3 times a day orally for 12 weeks as a course of treatment; Control group did not received other drugs in addition to taking the levodopa. The efficacy was measured according to the scores of Unified PD Rating Scale （UPDRS） pre and post therapy. The adverse reactions was observed. Results Pramipexole total effective rate was 86. 67% , significantly better than the bromocriptine group（75.00% ） , the frequency of adverse reactions was no significant difference between the two groups. Conclusions For patients taking levodopa plus pramipexole can achieve remission of their motor symptoms, reduce consumption of levodopa, improved adverse reactions of levodopa.

关 键 词：帕金森病 普拉克索 左旋多巴 溴隐亭 

分 类 号：R742.5[医药卫生—神经病学与精神病学]